Table 1.
Clinical study designs
| Study acronym | Design | Treatment arms | Mean dose(mg) (SD) | Length of acute phase (weeks) | Baseline symptom thresholds |
|---|---|---|---|---|---|
| HMAYa | Randomized, double blind and fixed dose | DLX (40 or 60 mg BID) | NA | 9 | HAMD‐17 total score ≥ 15 |
| PRX (20 mg QD) | |||||
| PLB | |||||
| CGI‐S ≥ 4 | |||||
| HMAYb | Randomized, double blind and fixed dose | DLX (40 or 60 mg BID) | NA | 9 | HAMD‐17 total score ≥ 15 |
| CGI‐S ≥ 4 | |||||
| PRX (20 mg QD) | |||||
| PLB | |||||
| HMCR | Randomized, double blind and fixed dose | DLX (60, 90 and 120 mg QD) | NA | 8 | MADRS ≥ 22 |
| ESC (10 and 20 mg QD) | |||||
| PLB | |||||
| CGI‐S ≥ 4 | |||||
| HMFT | Randomized, open label and flexible dose | DLX (60–120 mg QD) | DLX = 70.8 (22.0) | 12 | PHQ‐9 ≥ 16 |
| Generic SSRIs | CIT = 33.1 (9.1) | QIDS‐SR ≥ 20 | |||
| CIT (20–40 mg QD) | FLX = 42.3 (16.1) | ||||
| FLX (20–80 mg QD) | PRX = 29.0 (8.4) | ||||
| PRX (20–50 mg QD) | SER = 109.0 (38.8) | ||||
| SER (50–200 mg QD) |
BID, twice daily; CIT, citalopram; DLX, duloxetine; CGI‐S, Clinical Global Impression‐Severity; ESC, escitalopram; FLX, fluoxetine; HAMD‐17, 17‐item Hamilton Depression Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; NA, not applicable; PHQ‐9, Patient Health Questionnaire Depression Scale; PLB, placebo; PRX, paroxetine; QD, once daily; QIDS‐SR, 16‐item Quick Inventory of Depressive Symptomatology (self‐report); SD, standard deviation; SER, sertraline.